Amyotrophic lateral sclerosis, or ALS, is a devastating condition in which the nerve cells controlling movement progressively die, robbing patients of the ability to walk, speak and eventually breathe. Treatments remain few and modest, and the search for something that can slow the disease has been long and frustrating. Now, an inventive delivery strategy is generating cautious excitement.
Researchers have packaged a potential ALS therapy inside tiny sacs produced by cells themselves, and delivered the payload through the nose rather than by injection. In mice, this approach delayed the onset of the disease, suggesting that the treatment reached the nervous system in a way that mattered. The nasal route is attractive because it offers a direct path toward the brain and spinal cord, bypassing the barriers that make it so hard to get drugs into the central nervous system. The work is still at the animal stage, and translating it into a therapy for people will take years, but it demonstrates how clever packaging and delivery can revive treatments that previously seemed out of reach.
